Skip to main content

Table 1 Comparison of baseline characteristics and concomitant use drugs between the two groups

From: Effects of 6-month eicosapentaenoic acid treatment on postprandial hyperglycemia, hyperlipidemia, insulin secretion ability, and concomitant endothelial dysfunction among newly-diagnosed impaired glucose metabolism patients with coronary artery disease. An open label, single blinded, prospective randomized controlled trial

  Non-EPA group (n = 53) EPA group (n = 54) P value
Age (y.o) 68.9 ± 8.8 67.8 ± 9.1 0.49
Sex (male, n, %) 43 (81.1 %) 44 (81.5 %) 0.84
Coronary risk factor
 Hypertension (n, %) 49 (92.5 %) 48 (88.9 %) 0.76
 Dyslipidemia (n, %) 53 (100 %) 54 (100 %) 0.99
 Smoking (n, %) 4 (7.5 %) 5 (9.3 %) 0.98
Concomitant use drug
 Statin (n, %) 44 (83.0 %) 46 (85.2 %) 0.97
 Calcium channel blocker (n, %) 30 (56.6 %) 27 (50.0 %) 0.62
 ACEI/ARB (n, %) 35 (66.0 %) 40 (74.1 %) 0.49
  1. Values are presented as number (%) or mean ± standard deviation, as indicated
  2. ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker